Infertility Drugs Market
Number of pages: 100 | Report Format: PDF | Published date: May 18, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 3.47 billion |
|
Revenue Forecast in 2031 |
US$ 5.81 billion |
|
CAGR |
5.90% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, and End User and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global infertility drugs market was valued at US$ 3.47 billion in 2022 and is expected to register a revenue CAGR of 5.90% to reach US$ 5.81 billion by 2031.
Infertility Drugs Market Fundamentals
Infertility refers to the difficulty conceiving because of problems with their reproductive systems. As age advances, women's fertility gradually declines. Men's infertility, on the other hand, can be attributed to an unhealthy lifestyle, smoking, and alcohol intake. Hormonal and ovulation-regulating drugs, alongside minor surgical operations, are typically used to treat infertility.
Many new trends and opportunities are influencing the infertility drugs market. For instance, as genetic testing and knowledge about individual variations progress, personalized infertility treatment is becoming more prevalent. Genetic testing identifies specific fertility issues, and medication can be customized to address the underlying causes more effectively. Moreover, gonadotropin-releasing hormone (GnRH) agonists and antagonists are increasingly used to prevent premature ovulation during infertility treatments. GnRH agonists were traditionally used, but GnRH antagonists have gained popularity due to their shorter duration of action and ability to suppress hormone release, resulting in improved cycle control quickly.
Market players in the infertility drugs market are increasingly employing various strategies to increase their revenue share. Companies in the Infertility Drugs Market often focus on expanding their product portfolio to offer a comprehensive range of medications and treatment options. This includes developing new drugs, improving existing formulations, and introducing innovative delivery systems or devices. By providing diverse solutions, companies can cater to different patient needs and increase their market share. Moreover, effective marketing and promotional strategies are vital in raising awareness about infertility treatments and attracting potential patients.
[75675]
Infertility Drugs Market Dynamics
One of the primary factors fuelling the growth of the infertility drugs market is the rising incidence of infertility. According to the World Health Organization's 2022 estimates, about 17.5% of the adult population is impacted by infertility, meaning that approximately one in every six people worldwide is affected. Moreover, recent studies have revealed that obesity and smoking are the leading causes of infertility. For instance, Harvard University reports that overweight men have an 11% higher chance of producing less sperm than normal-weight men, and a 39% higher chance of producing no sperm at all. Additionally, obese males have a 42% higher likelihood of having a low sperm count and an 81% higher chance of producing no sperm.
Research and development are paving the way for novel infertility drugs. For instance, a recent study conducted by Nagoya University in Japan in March 2023 revealed that ATP, the energy currency within cells, functions as a neurotransmitter in the brain and stimulates mammalian ovulation. The results of this study have the potential to open avenues for the development of successful solutions for addressing infertility among humans and ovulation disorders in livestock.
Additionally, many top players are increasing their geographic reach by launching generic versions of drugs in developing countries. For instance, in December 2019, Mankind launched its generic dydrogesterone tablets to treat infertility and pregnancy-related complications in India. The launch of this drug marks a significant milestone, as the company is now the first Indian and second global firm to successfully develop the drug. Moreover, many pipeline drugs in treating infertility are expected to increase the revenue CAGR of the global infertility drugs market in the forecast years. For instance, Rekovelle of Ferring Pharmaceuticals has entered phase 3 of clinical trials. According to the European Medicines Agency, Rekovelle is just as effective as GONAL-f, a gonadotropin medicine used to stimulate the ovaries.
However, the high cost of drugs, limited insurance coverage, and the increasing preference for alternative treatments such as in vitro fertilization (IVF) is the prominent restraining factor in the infertility drugs market.
Infertility Drugs Market Ecosystem
The global infertility drugs market is analyzed from the following perspectives: drug class, distribution channel, and end user and region.
Infertility Drugs Market by Drug Class
[978786]
Based on drug class, the global infertility drugs market is segmented into selective estrogen receptor modulators (SERMs), gonadotropins, dopamine agonists, and aromatase inhibitors.
The gonadotropin segment accounted for 38.70% revenue share in 2022 in the global infertility drugs market. The growth of gonadotropin drugs is majorly attributed to their high usage in assisted reproductive technology. Additionally, gonadotropin medications have proven to be highly efficient for females experiencing irregular ovulation or decreased ovarian reserve, producing multiple follicles. Furthermore, gonadotropin drugs provide more treatment procedure flexibility. They can be used in various regimens, such as long or short protocols, depending on the unique demands of the patient.
Infertility Drugs Market by Gender
Based on gender, the global infertility drugs market is segmented into males and females.
The female segment dominated the global infertility drugs market accounting for 73.42% of the revenue share 2022. Research shows a significant surge in the number of women who face difficulty conceiving due to female infertility. The Centers for Disease Control and Prevention in 2022 reports states that around 19% of married women aged 15 to 49 years, who have never given birth, suffer from infertility after trying to conceive for a year. Moreover, almost 26% of women in this category may experience difficulties getting pregnant or carrying a pregnancy to full term, which is impaired fecundity. This incidence rate is expected to increase in the forecast period due to hormonal issues, such as Polycystic Ovary Syndrome (PCOS), increasing among females. The 2022 estimates of the Centers for Disease Control and Prevention state that PCOS is one of the most frequent causes of female infertility, affecting 6% to 12% (up to 5 million) of reproductive-age women in the United States.
Infertility Drugs Market by Distribution Channel
Based on distribution channels, the global infertility drugs market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies.
The hospital pharmacies segment accounted for 55.45% of revenue share in 2022. This is majorly attributed to the increasing number of patients visiting hospitals and the easy accessibility of drugs. Moreover, hospitals maintain high-quality control standards in their pharmacies to ensure that the medications dispensed are safe and effective. They source drugs only from trustworthy manufacturers, maintain proper storage conditions, and follow standardized protocols to minimize the risk of medication errors or counterfeit drugs.
Infertility Drugs Market by Region
Based on the region, the global infertility drugs market is segmented into North America, Europe, Asia Pacific, Latin America, & the Middle East & Africa.
The North America region dominated the infertility drugs market with 39% of the revenue share. This is majorly attributed to the increasing incidence of infertility in North America. According to the National Institute of Child Health and Human Development, in 2018 the United States, around 9% of males and 11% of women of reproductive age suffer from fertility issues. Moreover, many top players in North America have led to the development of advanced infertility drugs and treatments in the region. The increasing demand for these drugs and treatments is expected to drive the growth of the infertility drugs market in North America in the forecast years.
The Asia Pacific infertility drugs market is projected to grow substantially in the coming years due to the increasing awareness of infertility and the presence of many market players, increasing their geographic reach. There is also a rise in the number of infertility cases in the region, further fueling the demand for infertility drugs. According to the World Health Organization (WHO), India's infertility prevalence ranges between 3.9% and 16.8% in 2022. The market revenue share is also expected to increase due to increasing healthcare standards, and disposable income in Asia Pacific is supporting the revenue share of the infertility drugs market.
Infertility Drugs Market Competitive Landscape
The competitive landscape of the global infertility drugs market is highly competitive with the presence of several key players such as Teva Pharmaceuticals, and Sanofi S.A. These companies are constantly engaged in research and development activities to introduce innovative products in the market and gain a competitive edge. Additionally, strategic collaborations, mergers, and acquisitions are key strategies these players adopt to expand their market presence.
Some of the prominent companies having the largest revenue share in the global infertility drugs market are,
Infertility refers to the inability of a couple to conceive due to issues with the female or male reproductive system.
The global infertility drugs market is expected to reach US$ 5.81 billion by 2031.
The global infertility drugs market has experienced significant growth in recent years, driven by the rising incidence of infertility and increasing research and development for infertility drugs.
The global infertility drugs market is expected to register a CAGR of 5.90% in the forecast years.
North America accounted 39% of the revenue share in the global infertility drugs market in 2022.
*Insights on financial performance are subject to the availability of information in the public domain
Recommended Reports